These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 28904197)

  • 21. Tim-3 blocking rescue macrophage and T cell function against Mycobacterium tuberculosis infection in HIV+ patients.
    Sada-Ovalle I; Ocaña-Guzman R; Pérez-Patrigeón S; Chávez-Galán L; Sierra-Madero J; Torre-Bouscoulet L; Addo MM
    J Int AIDS Soc; 2015; 18(1):20078. PubMed ID: 26486200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TLR ligand induced IL-6 counter-regulates the anti-viral CD8(+) T cell response during an acute retrovirus infection.
    Wu W; Dietze KK; Gibbert K; Lang KS; Trilling M; Yan H; Wu J; Yang D; Lu M; Roggendorf M; Dittmer U; Liu J
    Sci Rep; 2015 May; 5():10501. PubMed ID: 25994622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiretroviral therapy-induced dominant interleukin-2 HIV-1 Gag CD4+ T cell response: evidence of functional recovery of HIV-1-specific CD4+ T cells.
    Tsalimalma K; Kordossis T; Choremi-Papadopoulou E
    Scand J Immunol; 2011 Mar; 73(3):256-65. PubMed ID: 21204901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-1 has a unique capacity to inhibit allergen-specific human CD4
    Rosskopf S; Jahn-Schmid B; Schmetterer KG; Zlabinger GJ; Steinberger P
    Sci Rep; 2018 Sep; 8(1):13543. PubMed ID: 30201974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection.
    Zheng NN; McElrath MJ; Sow PS; Hawes SE; Diallo-Agne H; Stern JE; Li F; Mesher AL; Robinson AD; Gottlieb GS; Huang Y; Kiviat NB
    J Virol; 2007 Sep; 81(17):9061-71. PubMed ID: 17582003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4
    Beavis PA; Henderson MA; Giuffrida L; Davenport AJ; Petley EV; House IG; Lai J; Sek K; Milenkovski N; John LB; Mardiana S; Slaney CY; Trapani JA; Loi S; Kershaw MH; Haynes NM; Darcy PK
    Cancer Immunol Res; 2018 Sep; 6(9):1069-1081. PubMed ID: 30018045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytokine production from murine CD4 and CD8 cells after mannan-MUC1 immunization.
    Lees CJ; Apostolopoulos V; McKenzie IF
    J Interferon Cytokine Res; 1999 Dec; 19(12):1373-9. PubMed ID: 10638706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade.
    Porichis F; Kwon DS; Zupkosky J; Tighe DP; McMullen A; Brockman MA; Pavlik DF; Rodriguez-Garcia M; Pereyra F; Freeman GJ; Kavanagh DG; Kaufmann DE
    Blood; 2011 Jul; 118(4):965-74. PubMed ID: 21652684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-necrosis factor impairs CD4(+) T cell-mediated immunological control in chronic viral infection.
    Beyer M; Abdullah Z; Chemnitz JM; Maisel D; Sander J; Lehmann C; Thabet Y; Shinde PV; Schmidleithner L; Köhne M; Trebicka J; Schierwagen R; Hofmann A; Popov A; Lang KS; Oxenius A; Buch T; Kurts C; Heikenwalder M; Fätkenheuer G; Lang PA; Hartmann P; Knolle PA; Schultze JL
    Nat Immunol; 2016 May; 17(5):593-603. PubMed ID: 26950238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD4(+) T cells and gamma interferon in the long-term control of persistent friend retrovirus infection.
    Iwashiro M; Peterson K; Messer RJ; Stromnes IM; Hasenkrug KJ
    J Virol; 2001 Jan; 75(1):52-60. PubMed ID: 11119573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD8+ T cells of chronic HCV-infected patients express multiple negative immune checkpoints following stimulation with HCV peptides.
    Barathan M; Mohamed R; Vadivelu J; Chang LY; Vignesh R; Krishnan J; Sigamani P; Saeidi A; Ram MR; Velu V; Larsson M; Shankar EM
    Cell Immunol; 2017 Mar; 313():1-9. PubMed ID: 28104239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer.
    Heon EK; Wulan H; Macdonald LP; Malek AO; Braunstein GH; Eaves CG; Schattner MD; Allen PM; Alexander MO; Hawkins CA; McGovern DW; Freeman RL; Amir EP; Huse JD; Zaltzman JS; Kauff NP; Meyers PG; Gleason MH; Overholtzer MG; Wiseman SS; Streutker CD; Asa SW; McAlindon TP; Newcomb PO; Sorensen PM; Press OA
    Biochem Biophys Res Commun; 2015 Aug; 464(1):360-6. PubMed ID: 26141233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options.
    Velu V; Shetty RD; Larsson M; Shankar EM
    Retrovirology; 2015 Feb; 12():14. PubMed ID: 25756928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-specific TGF-beta-positive CD4+ T cells do not express regulatory surface markers and are regulated by CTLA-4.
    Elrefaei M; Burke CM; Baker CA; Jones NG; Bousheri S; Bangsberg DR; Cao H
    AIDS Res Hum Retroviruses; 2010 Mar; 26(3):329-37. PubMed ID: 20433405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults.
    Boer MC; van Meijgaarden KE; Goletti D; Vanini V; Prins C; Ottenhoff TH; Joosten SA
    Tuberculosis (Edinb); 2016 Mar; 97():163-71. PubMed ID: 26750180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.
    Simon B; Harrer DC; Schuler-Thurner B; Schaft N; Schuler G; Dörrie J; Uslu U
    Exp Dermatol; 2018 Jul; 27(7):769-778. PubMed ID: 29704887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination Immune Checkpoint Blockade to Reverse HIV Latency.
    Van der Sluis RM; Kumar NA; Pascoe RD; Zerbato JM; Evans VA; Dantanarayana AI; Anderson JL; Sékaly RP; Fromentin R; Chomont N; Cameron PU; Lewin SR
    J Immunol; 2020 Mar; 204(5):1242-1254. PubMed ID: 31988180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency of cytokine-producing T cells in HIV-infected patients treated with stavudine, didanosine, and ritonavir.
    Levacher M; Bouscarat F; Landman R; Chau F; Damond F; Gaudebout C; Mathez D; Leibowitch J; Saimot AG; Sinet M
    AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1869-75. PubMed ID: 11118072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Programmed cell death-1 (PD-1) and T-cell immunoglobulin mucin-3 (Tim-3) regulate CD4+ T cells to induce Type 2 helper T cell (Th2) bias at the maternal-fetal interface.
    Wang S; Zhu X; Xu Y; Zhang D; Li Y; Tao Y; Piao H; Li D; Du M
    Hum Reprod; 2016 Apr; 31(4):700-11. PubMed ID: 26908841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blockade of CTLA-4 decreases the generation of multifunctional memory CD4+ T cells in vivo.
    Rudolph M; Hebel K; Miyamura Y; Maverakis E; Brunner-Weinzierl MC
    J Immunol; 2011 May; 186(10):5580-9. PubMed ID: 21478403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.